Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Empagliflozin/Linagliptin/Metformin HCl ER Tablet vs Trijardy XR in Fed Condition
NCT07691203Phase 1Completed
- Sponsor
- Humanis
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin + linagliptin + metformin in type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) (2 arms), sponsored by Humanis. Primary endpoints: Maximum concentration at 72 hours, Area under the plasma concentration-time curve from time 0 to last collection time at 48 hours and 1 more. Started Mar 2026; status: completed.
02
Drugs
empagliflozin + linagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT07691203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691203.